Thoracoscopic Talc Pleurodesis Versus Bleomycin -Tranxemic Acid Mixture Injection in Chest Tube in Malignant Pleural Effusion

Comparison Between Pleurodesis by a Combination of Bleomycin and Tranxemic Acid Solution and Thoracoscopic Talc Poudrage in Malignant Pleural Effusion

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06744946

Enrollment

Registered

2024-12-20

Start date

2024-09-01

Completion date

2024-12-04

Last updated

2024-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Pleural Effusions (Mpe)- Pleurodesis, Pleurodesis

Keywords

Talc -pleurodesis-bleomycin

Brief summary

Comparing Two Methods to Treat Fluid Build-up in Chest for Cancer Patients:Talc Powder Surgery versus Chest Tube Medicine.

Detailed description

Closure of the space where the effusion is recurrently accumulated through talc poudrage in thoracoscopy or bleomycin - tranxemic acid solution injection in chest tube.

Interventions

PROCEDUREthoracoscope

bleomycin- tranxemic acid mixture pleurodesis versus thoracoscopic talc poudrage

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

comparing between two groups of thirty patients each,the first group will include talc poudrage pleurodesis and the second include chest tube injection of a mixture of bleomycin and tranxemic acid

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- 1. Adult patients (more than 18 years) with malignant pleural effusion or highly suspected exudate. 2\. Fit patients for the procedure selected.

Exclusion criteria

1. Inability to provide informed consent for the procedure. 2. Hemodynamically unstable patients. 3. Bleeding diathesis. 4. Uncontrolled cough. 5. Hypoxic index less than 300. 6. Endobronchial obstruction. 7. Pleural thickening with trapped lung.

Design outcomes

Primary

Measure	Time frame	Description
Dyspnea Borg Scale	one month	the rate of shortness of breath from number 0 to number 10

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026